Primary Retinal Detachment
Primary Retinal Detachment
Primary Retinal Detachment
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
158<br />
7 Pharmacological Approaches to Improve Surgical Outcomes<br />
30. Scott IU, Flynn HW Jr, Murray TG, Feuer WJ (2003) Perfluoron study<br />
group. Outcomes of surgery for retinal detachment associated with<br />
proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter<br />
study. Am J Ophthalmol 136:454–463<br />
31. Blumenkranz MS, Claflin A, Hajek AS (1984) Selection of therapeutic<br />
agents for intraocular proliferative disease: cell culture evaluation.<br />
Arch Ophthalmol 102:598–604<br />
32. Blumenkranz MS, Hartzer MK, Hajek AS (1987) Selection of therapeutic<br />
agents for intraocular proliferative disease. II. Differing antiproliferative<br />
activity of the fluoropyrimidines. Arch Ophthalmol<br />
105:396–399<br />
33. Williams RG, Chang S, Comaratta M, Simoni G (1996) Does the presence<br />
of heparin and dexamethasone in the vitrectomy infusate reduce<br />
reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin<br />
Exp Ophthalmol 234: 496–503<br />
34. Peyman GA, Cheema R, Conway MD, Fang T (2000) Triamcinolone<br />
acetonide as an aid to visualization of the vitreous and the posterior<br />
hyaloid during pars plana vitrectomy. Retina 20:554–555<br />
35. Barrada A, Peyman GA, Case J, Fishman G, Thomas A, Fiscella R (1984)<br />
Evaluation of intravitreal 5-fluorouracil, vincristine, VP16, doxorubicin,<br />
and thiotepa in primate eyes. Ophthalmic Surg 15:767–769<br />
36. Berger AS, Cheng CK, Pearson A, Ashton P, Crooks P, Cynkowski T,<br />
Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release corticosteroid-5-fluorouracil<br />
conjugate in the treatment of experimental<br />
proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37:2318–<br />
2325<br />
37. Rubsamen PE, Davis P, Hernandez E, O’Grady G, Cousins SW (1994)<br />
Prevention of experimental proliferative vitreoretinopathy with a biodegradable<br />
intravitreal implant for the sustained release of fluorouracil.<br />
Arch Ophthalmol 112: 407–413<br />
38. Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, and Fisher<br />
SK (1983) Ocular toxicity of fluorouracil after vitrectomy.Am J Ophthalmol<br />
96: 43–51<br />
39. Hartzer MK, Blumenkranz MS, Hajek AS, Dailey WD, Cheng M,<br />
Margherio AS (1989) Selection of therapeutic agents for the treatment<br />
of intraocular proliferative disease. Part 3. Effects of fluoropyrimidines<br />
on cell-mediated contraction. Exp Eye Res 48:321–328<br />
40. Berger AS, Cheng CK, Pearson A, Ashton P, Crooks P, Cynkowski T,<br />
Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release cortico-